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dialysis-related peritonitis in two patientsDear Editor,
Microbacteria are coryneform Gram-positive rods widely
found in the environment, for example, in soil.1 Recently,
they have been recognized as rare pathogens in humans.1
We report two cases of peritonitis related to continuous
cycling peritoneal dialysis (CCPD) caused by Micro-
bacterium spp.
The first patient was an 80-year-old patient on CCPD
admitted due to cloudy peritoneal fluid. Two weeks prior
to admission, she had peritonitis caused by Acinetobacter
spp. treated with empirical vancomycin and oral cipro-
floxacin; vancomycin was discontinued after culture re-
sults and ciprofloxacin was discontinued prematurely by
the patient because of digestive adverse effects. Cytology
of the peritoneal fluid revealed 1070 leukocytes/mm3 and
a neutrophil count of 55%. Oral ciprofloxacin and intra-
peritoneal vancomycin were readministered. The aerobic
culture grew two types of organisms. One was identified by
matrix assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOF MS, Bruker Daltonics, Bill-
erica, MA) as Acinetobacter spp. and the other as Micro-
bacterium aurum (identification score of 2.115 using
Bruker BioTyper database, version 3.1.0). 16S rRNA gene
sequencing performed by aligning multiple overlapping
sequences using Lasergene 5 package (DNAStar, Madison,
WI, USA) and compared using the Web-based BLAST 2 Se-
quences software tool (www.ncbi.nlm.nih.gov/blast/
bl2seq/wblast2.cgi)1 identified M. aurum with 99.51%
base pair homology. Minimum inhibitory concentration
(MIC) using Etest (bioMe´rieux, Marcy l’Etoile, France) of
this isolate is shown in Table 1. M. aurum was again
recovered in the peritoneal fluid on Day 1, Day 2 and Day 7
after the start of antibiotic treatment. Oral ciprofloxacin
was continued for 3 weeks and led to <50 leukocytes/mm3
at the end of treatment. However, an episode of repeat
peritonitis occurred at 4 months follow-up.http://dx.doi.org/10.1016/j.jmii.2014.03.008
1684-1182/Copyright ª 2014, Taiwan Society of Microbiology. Publishe
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/The second patient was a 48-year-old woman on CCPD
admitted with abdominal pain, cloudy effluent, and
impaired drainage, with signs of peritonitis in the peri-
umbilical region and redness around the exit site, with
purulent secretion. Cytology of the peritoneal fluid
revealed 767 leukocytes/mm3 and neutrophil count of 64%.
Empiric intraperitoneal aztreonam and vancomycin were
given with favorable initial evolution. Three days later,
antibiotics were switched to oral amoxicillin/clavulanic
acid and intraperitoneal vancomycin based on isolation of
Staphylococcus aureus and Gram-positive coryneform
rods. MALDI-TOF MS could not identify the rods reliably
(identification score of 1.849 for Microbacterium lacticum)
but 16S rRNA gene sequences showed 99.93% similarity
with Microbacterium oxydans. The MIC of this isolate is
shown in Table 1. Microbacterium spp. was again isolated
from three consecutive samples of peritoneal fluid within 1
week, and refractory peritonitis was treated by removal of
the peritoneal catheter 15 days after initial presentation.
After the present episode, she had episodes of peritonitis:
one caused by coagulase-negative staphylococci, one by
Streptococcus mitis, and three by Corynebacterium
amycolatum.
This is believed to be the first case series of CCPD-
related peritonitis caused by Microbacterium spp. Only
three case reports have been published so far in which16S
rRNA gene sequencing was applied and found Micro-
bacterium resistens, Microbacterium paraoxydans and
Microbacterium spp. in CCPD-related peritonitis.2e4 The
clinical relevance of these findings is that microbacteria
should not be considered as contaminants when they are
found in peritoneal fluid. When microbacteria are found,
the history of environmental contact, for example with
soil, should be obtained. Microbacteria in our case series
were susceptible to penicillin and cephalosporin; these
antibiotics could be used in treating CCPD-related perito-
nitis caused by microbacteria. Yet, they should be usedd by Elsevier Taiwan LLC. This is an open access article under the
4.0/)
Table 1 MIC of Microbacterium aurum and Microbacterium oxydans isolated in this case series
MIC, mg/L (susceptibility according to EUCAST non-species related breakpoints)
Ampicillin Amoxicillin/clavulanic acid Cefuroxime Ceftriaxone Ciprofloxacin
M. aurum 0.75 (S) 0.75 (S) 1.5 (S) 0.38 (S) 1.0 (S)
M. oxydans 1.5 (S) 2.0 (S) 4.0 (S) 2.0 (S) NP
EUCASTZ European Committee on Antimicrobial Susceptibility Testing; MICZminimum inhibitory concentration; NPZ not performed;
S Z susceptible.
Correspondence 465after determining MIC because MIC is possibly species
dependent. The MIC of M. oxydans was consistently higher
than that of M. aurum in our case series, which might
explain the difficulties in treating the second patient. In
one case report, M. resistens appeared to be resistant to
ceftriaxone.3
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